



MMJ Group Holdings Limited
Suite 518, Level 5
165-167 Phillip Street
Sydney NSW Australia 2000

www.mmjgh.com.au
info@mmjgh.com.au

ASX RELEASE

10 December 2020

MMJ Investment Portfolio Report as at 30 November 2020

MMJ Group Holdings Limited (ASX: MMJ/OTC Code MMJF) ("MMJ") is an Australian-listed company whose core business is holding minority investments across along the cannabis value-chain in Australia, Canada and Europe. MMJ is also able to make investments in sectors outside of cannabis, such as but not limited to, natural resources, pharmaceuticals and software services technology,

MMJ Investment Portfolio Report

MMJ is pleased to provide the MMJ Investment Portfolio Report as at 30 November 2020 which includes the disclosure pursuant to Listing Rule 4.12.

Investor and Media Enquiries

Announcement authorised for release to ASX by:
Jim Hallam
Chief Financial Officer and Company Secretary
E: Compsec@mmjgh.com.au

About MMJ

MMJ Group Holdings Limited (ASX:MMJ) ("MMJ") is a listed global cannabis investment company (ABN 91 601 236 417) whose core business is holding minority investments across along the cannabis value-chain including cultivation, extraction, crystallisation, product manufacture, retail and patient services. in Australia, Canada and Europe. MMJ is also able to make investments in sectors outside of cannabis, such as but not limited to, natural resources, pharmaceuticals and software services technology.

Important Notice

This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.



Investment Portfolio Report

30 November 2020

MMJ's Investments sit across most of the cannabis and hemp value chain

Capital is allocated to potential market leaders, consolidators and takeover targets



Important Notice

This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. All information is unaudited unless stated otherwise. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. The investment returns shown are historical and no warranty can be given for future performance. Historical performance is not a reliable indicator of future performance. Due to the volatility in a Company's underlying assets and other risk factors associated with investing, investment returns can be negative, particularly in the short-term.

About MMJ

MMJ (ASX Code MMJ/OTC Code MMJF) is an Australian-listed company whose core business is holding minority investments across along the cannabis value-chain including cultivation, extraction, crystallisation, product manufacture, retail and patient services. in Australia, Canada and Europe. MMJ is also able to make investments in sectors outside of cannabis, such as but not limited to, natural resources, pharmaceuticals and software services technology.

MMJ is the only listed Australian investment company which offers the opportunity to Australian investors to invest in unlisted and listed cannabis-related businesses in Australia and offshore.

MMJ has a proven track record in acquiring and realising considerable value from its cannabis related investments.

Since 2015, MMJ has created a significant number of investment opportunities from its connections in Canada and Australia in the private investment sector and realised exits when it is to the benefit of MMJ and its shareholders:

20 Primary Acquisitions
 9 Follow on investments¹
 4 Private to public
 10 Sale of investments

MMJ Investment Performance²

MMJ Historical Performance - period ended					30-Nov-20
	1 month	3 months	Financial year to date	12 months	Since inception
Pre tax return	(0)%	(7)%	(15)%	(44)%	(20)%
Benchmark	48%	27%	24%	(8)%	(22)%
Out/(under) performance	(48)%	(34)%	(38)%	(36)%	2%

For MMJ's latest investor presentations and news, please visit www.mmjgh.com.au

General Investor Queries

E: info@mmjgh.com.au

W: mmjgh.com.au

Share Registry

Automic Registry Services

P: 1300 288 664

W: automic.com.au

Performance Update

Net Tangible Asset Value Per Share Before Tax³ as at 30 November 2020

\$0.1687

Total Portfolio as at 30 November 2020

\$39m

Investment Return Since Inception⁴ as at 30 November 2020 (per annum)

(20)% pa

Key Metrics as at	30-Nov-20	AUD
Net Asset Value	m	39
Investee Porfolio (ex cash)	m	35
Cash	m	4
Net Tangible Asset per share - pre-tax (issued pursuant to LR 4.12)		0.1687
Net Tangible Asset per share - post tax (issued pursuant to LR 4.12)		0.1687
Net Asset Value per share		0.1698
MMJ share price (ASX)		0.125
Market capitalisation	m	29
Number of investments (ex cash)		11
ASX Investment Type		Listed Investment Company
Initial Public Offering Date (inception date)		22-Jan-15
No. of ordinary shares on issue	m	230

MMJ shareholder communications

MMJ is holding a webinar conference call on 16 December 2020 to allow MMJ shareholders and interested parties to hear an update on global cannabis markets and key investments and to also ask questions.

Copies of announcements related to MMJ's operations may be found on the MMJ website: www.mmjgh.com.au.

¹ Includes investments in existing investees

² MMJ uses the Alternative Harvest ETF (ticker symbol MJ) as its investment benchmark for the MMJ portfolio as it is a highly liquid portfolio trading in the North American market (where most of MMJ's holdings are based). MJ is listed on the New York Stock Exchange

³ Net Tangible Asset Value per share – net tangible assets per share before tax on unrealised gains on investment portfolio

⁴ Inception is 30 June 2018 being the date when MMJ commenced accounting for investments as an investment entity

MMJ NEWS**Performance of MMJ Portfolio for November 2020****Investment Performance for Year to Date**

MMJ's portfolio management is focussing on:

- a) Creating a diversified portfolio of CBD and cannabis investments in cultivation, extraction and consumer products with material investments in Weed Me, WeedMD, Sequoya, Harvest One, Southern Cannabis Holdings and Bespoke.
- b) Supporting the intention of the public listing of Embark Health which was announced earlier in 2020.

The current downturn in global financial markets will delay liquidity events in some of these material investments – however the individual businesses are realising opportunities to capitalise on the growing demand for CBD and cannabis products in North America and Europe.

During the month ended 30 November 2020, MMJ NAV generated a nil% return which compared to positive 48% for the benchmark return for the same period. The benchmark consists of listed North American cannabis securities. With 79% of the MMJ portfolio in unlisted cannabis securities, the rerating of the listed markets provides some optimism for valuation uplifts when the unlisted investees (principally Embark Health and Weed Me) achieve public listing which is expected mid-2021.

The Australian share market recognised the positive momentum during the first half of December 2020 with the MMJ share price increasing from 12.5 cents to 18 cents with a high of 21 cents.

MMJ Portfolio Update

A number of larger investments provided updates on their operating performance and business plan initiatives:

a) Harvest One

Harvest One Cannabis Inc. ("Harvest One" or the "Company") (TSX-V: HVT; OTCQX: HRVOF) announced its financial results for the three months ended 30 September 2020.

"Harvest One's financial performance in the first fiscal quarter demonstrates the positive impact of the Company's restructuring objectives over the last twelve months. The Company's financial results are moving in a positive direction with a significant reduction in operating and overhead costs. We have also made improvements on both sides of the balance sheet by improving working capital and reducing liabilities, setting a solid foundation for rejuvenated growth in 2021," said Gord Davey, President and Interim Chief Executive Officer of Harvest One. *"As the Strategic Review approaches conclusion, our leadership team has redefined the Company's commercial strategy to set positive momentum for our core consumer brands. We are executing many catalysts for growth within the fiscal year as they are critical to our strategic initiatives."*

Harvest One has repositioned itself from cultivation and processing to a non-capital-intensive hybrid cannabis CPG operation focused on both OTC non-infused and cannabis-infused products. The Company's brands including Dream Water, LivRelief and Satipharm have products in sleep, anxiety and pain categories and are distributed and sold in retail channels across Canada, the US, Europe and the Middle East. Throughout the past twelve months, the Company has undergone transformative changes by divesting of capital intensive and nonperforming cultivation assets to create a unique business model within the cannabis space.

The Company has a strong foundation of well-established consumer brands that are positioned for growth, as the Company looks to execute on key growth initiatives throughout the 2021 fiscal year and beyond.

Harvest One also made a key announcement during November when the United States Patent and Trademark Office granted its wholly-owned subsidiary Satipharm Ltd US Patent No. 10,555,906 covering Satipharm's proprietary Gelpell technology.

"Receipt of this patent represents an important milestone for Satipharm, completing the patenting process for key jurisdictions", said Gord Davey, President and Interim Chief Executive Officer of Harvest One. Mr Davey also said *"This patent, combined with our published Phase I and II clinical trials, further emphasizes the strength of the Satipharm brand as we pursue commercial partners for various pharmaceutical, nutraceutical and recreational applications. The issuance of this patent comes at an important time following the recent US election and the anticipated federal legalization of cannabinoids in the US".*

The Company has obtained patents covering Gelpell technology in the key markets, including the United States, Canada, United Kingdom, Australia and countries of the European Union.

b) Embark Health

Embark Health Inc. ("Embark" or the "Company") announced that it has been granted an amendment to its Health Canada licence for the sale of cannabis extracts, cannabis topicals and edible cannabis products from their facility in Delta, British Columbia.

The amendment to the Health Canada licence permits sales of Cannabis 2.0 products directly to Canadian Provinces & Territories and allows the Company to further expand its existing and future product offerings to the medical and recreational consumer markets with concentrates, extracts and nanoemulsified topical and edible products.

c) WeedMD

WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) ("WeedMD" or the "Company"), a federally-licensed producer and distributor of medical-grade cannabis, announced its financial results for the three and nine months ended 30 September 2020.

"Our revenue growth quarter-over-quarter demonstrates the current momentum we are seeing in our business, particularly in our adult-use segment where consumer appeal for our Color Cannabis products continues to grow," said Angelo Tsebelis, CEO. *"With our expanded national sales team, we are making steady traction in establishing new retail accounts and shipping product across the country at a faster pace. We remained highly focused on delivery of our expanding quality product portfolio to consumers during the quarter in the adult-use market and our proprietary direct-to-patient medical channel leading to improved margins going forward."*

For the three and nine months ended 30 September 2020, WeedMD recorded net sales of CAD6.3m and CAD24.4m, respectively, compared to approximately CAD6.7m and CAD18m for the same periods ended 30 September 2019. Net revenue increased 8%, as compared to CAD5.9m during the second quarter of 2020.

MMJ's 2020 Annual General Meeting

MMJ held its Annual General Meeting virtually on 30 November 2020. MMJ's Chairman Peter Wall commented that *"the MMJ Board is delighted that our shareholders have strongly supported the recommendations by the Board including the proposal to broaden its existing investment mandate to include strategic investments in sectors outside of cannabis, such as but not limited to, natural resources, pharmaceuticals and software services technology, which will comprise no more than 25% of the Company's total consolidated assets at the time the investments are made."*

MMJ's Funding Position

MMJ is well positioned to create value from the existing portfolio with a liquid balance sheet and cashflows from investments:

- a) Total assets of \$39m with immaterial current liabilities.
- b) Cash of AUD3.7m and a portfolio of listed equities (CAD4.3m), listed convertible loans (CAD1.8m) and unlisted loan securities (CAD3.2m) which provide MMJ interest income with flexibility to fund flow on investments, effect timing of investment exits and MMJ's operating requirements.

Future Investment Opportunities

MMJ holds warrants (similar to 'options' in Australia) and contractual rights in a number of its existing listed and unlisted investments which provide opportunities for MMJ to make follow-on investments in businesses at a discount to current valuations and where MMJ is well placed to understand their potential returns. MMJ holds the right to make follow on investments:


- a) Sequoya (European CBD oil extraction)
- b) WeedMD (Canadian cannabis cultivation and cannabis oil extraction)
- c) Embark Health (Canadian cannabis and CBD oil extraction)
- d) Harvest One Cannabis (Canadian cannabis consumer and wellness products).

Embark Ventures Sector Update – November 2020

Over the course of November, MMJ stock has risen by 14% from 10.5c to 12.5c. Comparatively, the broader markets as represented by the ASX 200 have risen by 10% from 5927 to 6517 and our benchmark Alternative Harvest ETF has risen by approximately 48% from \$10.73 to \$15.92. Since the end of November, MMJ stock is up a further 46% to date and the stock recently closed at 18.

Clearly the results of the US elections continue to have a positive impact on cannabis equities worldwide. Since our last shareholder letter, the MORE Act has passed the US House of Representatives but is expected to fail at the senate as the senate is Republican controlled. As a reminder, in the US a bill needs to pass the House, Senate, and be signed by the President to become law. Once President-elect Joe Biden is sworn in, we are simply one senate seat away from federal legalization of cannabis in the United States. The next clear opportunity to flip the senate will come in the 2022 mid-terms. According to a November Gallup poll, a record 68% of Americans support legalizing cannabis. That's up from 60% in 2016. Clearly the winds of change are blowing, and it seems just a matter of time before there is a change in the United States that will have ramifications globally for Cannabis. Already, the United Nations Commission on Narcotic Drugs (CND) has recently accepted a World Health Organization (WHO) recommendation to remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs.

As cannabis becomes more mainstream, consumer market data that is emerging from several US states also appears to show an increasing demand for higher priced products which indicates increasing brand loyalty and consumers becoming more discriminating in terms of quality. This is a trend we have seen in the alcohol and beverage sector in the past as consumer palates become more sophisticated. We suspect similar trends are occurring within the Canadian space as well which bodes well for our investment strategy of focusing on companies producing higher quality/higher margin flower and extracts combined with strong branding strategies.



Source: Headset
© 2020 Marijuana Business Daily, a division of Anne Holland Ventures Inc. All rights reserved

The positive political news from the US, consistent domestic market growth (the Canadian cannabis market now exceeds \$3bln on an annualized basis), and what we suspect is significant short covering continues to propel Canadian equities higher, but we note there could be some challenges still ahead. While Canadian companies continue to show revenue growth and ink deals with US companies (see Aphria's recent transaction with Sweetwater as an example), they continue to struggle on the cost containment front. Yes, the total domestic market may eventually be double or triple where it is now and an opening up of the US market could produce further opportunities. But those things may also take longer to materialize than management teams are expecting. We would like to see the industry focus even more on cost containment to make sure that it can deal with either outcome. For our part we have highly encouraged portfolio company management teams to take a conservative approach on managing costs.

Within the MMJ portfolio we are pleased to report that Embark Health has received its sales license amendment from Health Canada. This is a major step for the company and will allow them to sell products directly to various provincial retail outlets instead of vending through a licensed sales group or just doing B2B transactions. Given their focus on higher quality solventless extraction and the increasing consumer preference for higher priced products as we noted above, we expect their branded products to show well at the various provincial level retail channels over the coming months.

Appendix One


1. The year to date performance of MMJ's NTA is detailed below⁵:

Table One

MMJ Historical Performance - financial year to date		30-Jun-18	30-Jun-19	30-Jun-20	31-Jul-20	31-Aug-20	30-Sep-20	31-Oct-20	30-Nov-20
Share price \$	AUD	0.335	0.245	0.096	0.100	0.093	0.094	0.105	0.125
Net Asset Value	AUD	0.2879	0.3721	0.1924	0.1695	0.1800	0.1747	0.1688	0.1698
NTA Post Tax \$	AUD	0.2860	0.3718	0.1925	0.1664	0.1789	0.1747	0.1686	0.1687
NTA Pre Tax \$	AUD	0.2900	0.3874	0.1976	0.1664	0.1816	0.1768	0.1689	0.1687
Net Return - pre tax NTA - year to date		n/a	34%	(49)%	(16)%	(8)%	(11)%	(15)%	(15)%
Premium/(discount) of share price to pre tax NTA		16%	(37)%	(51)%	(40)%	(49)%	(47)%	(38)%	(26)%

2. Chart One demonstrates the current discount of the MMJ share price to the pre-tax net tangible asset value (NTA).

Chart One



3. MMJ's investment portfolio is detailed in Table Two:

Table Two

Investment	CSE/TSXV/ TSX Code	Initial Investment date	Country	Company type	Investment structure	Business	MOIC (current portfolio)	Book Value (unaudited)	Weight	Book Value (unaudited)	Weight
							30-Nov-20 Times	30-Nov-20 AUDm		30-Jun-20 AUDm	
Harvest One	HVT	Apr-17	Canada	Listed	Shares and warrants	Health and wellness products	0.3	4.9	13%	6.6	23%
WeedMD Inc.	WMD.WM and WMD.DB	Sep-19	Canada	Listed	Convertible Notes and warrants	Cultivation	0.4	2.3	6%	3.4	9%
Listed investments								7.2	19%	10.0	33%
Embark Health		Jul-18	Canada	Unlisted	Shares and Warrants	Extraction	1.8	13.3	34%	13.2	28%
Weed Me		Dec-17	Canada	Unlisted	Shares, warrants	Cultivation	1.6	3.8	10%	6.0	13%
Sequoya		Jul-19	Canada/ Poland	Unlisted	Convertible note and shares	Extraction	1.0	4.0	10%	3.6	8%
Volero		May-19	Canada	Unlisted	Shares and warrants	Vapes	-	0.0	0%	1.3	6%
Bespoke		Aug-19	Canada	Unlisted	Bespoke A Limited Partnership holds shares and founders warrants issued by Bespoke Capital Acquisition Corp (TSX listed)	Investment in cannabis businesses	2.1	3.3	8%	3.5	4%
								24.3	63%	27.5	58%
VitaGenne		Nov-18	USA	Unlisted	Shares	Hemp CBD	2.1	0.8	2%	0.8	2%
Cannabis Access		Apr-18	Australia	Unlisted	Shares	Clinics	2.1	2.1	5%	2.1	2%
Martha Jane Medical		May-18	Australia	Unlisted	Shares	Extraction	0.8	0.5	1%	0.5	1%
J Supply		Feb-19	Canada	Unlisted	Shares	Retail stores	n/a	0.2	0%	0.2	1%
								3.5	9%	3.6	7%
Unlisted investments								27.8	72%	31.1	65%
Total portfolio								35.0	90%	41.1	99%
Cash								3.7	10%	1.0	1%
Total								38.7	100%	42.1	100%

⁵ The results for 30 June 2018, 30 June 2019 and 30 June 2020 are for the year ended on those dates

Appendix One continued

4. Listed securities held by MMJ

MMJ holds the following shares and warrants in listed investees:

Table Three⁶

Investment	No. of shares	Number of notes	No. of warrants	Exercise price of warrants (CAD)	Warrants expiry
Harvest One	55,557,994	-	17,083,333	0.06	Refer Appendix One 25 Sep 2022
WeedMD	-	6,000,000	3,750,000	1.80	

5. Divestments by MMJ

The details of the investments sold by MMJ are detailed below:

Table Four

Divested Investment	Method of sale	Partial/complete	Date of divestment	Net proceeds (AUDm)	Capital invested (AUDm)	MOIC
MediPharm Labs	on market	complete	Jun-20	34.1	9.2	3.7
Axiomm	takeover	complete	Sep-20	0.7	0.7	1.0
Bevcanna	on market	complete	Dec-19	0.6	0.8	0.8
Fire & Flower	on market	complete	Apr-20	1.5	1.0	1.5
Hemple	private sale	complete	Jul-20	0.3	1.3	0.2
Esense	on market	complete	May-18	0.4	0.5	0.8
Dosecann	takeover	complete	May-18	5.9	2.5	2.3
Total				43.5	16.0	2.7

Note:

- (a) MMJ sold its shares in Axiomm (as part of the sale of 100% of Axiomm to Embark Health) in exchange for Embark Health shares in September 2020.

6. Unlisted securities held by MMJ⁷

(a) Embark Health

MMJ was a foundation investor in Embark Health in July 2018 – the investment now comprises:

- i. 3.697m ordinary shares (approximately 12.4% shareholding) in Embark Health with a book value of CAD2.44 per share.
- ii. Warrants that provide the option for MMJ to acquire a further 1.0m shares at CAD1.75 each up with maturity date of two years after a Liquidity Event⁸.
- iii. Warrants that provide the option for MMJ to acquire a further 1.2m shares at CAD1.20⁹ each up with maturity date of two years after a Liquidity Event.
- iv. Warrants that provide the option for MMJ to acquire a further 1.125m shares at CAD4.80 each up with maturity date of two years after a Liquidity Event.

⁷ Information as at 30 November 2020

⁸ A Liquidity event is an initial public offering or a material sale event

⁹ Exercise price has based on MMJ book value of CAD2.44 per share

(b) Weed Me¹⁰

MMJ was a foundation investor in Weed Me in December 2017 which now comprises:

- i. 3.46m shares (book value of CAD1 per share) representing approximately 14% of Weed Me's issued capital and 3.46m warrants each convertible at CAD0.8666.

(c) Sequoya

MMJ was a foundation investor in Sequoya – the investment now comprises:

- i. CAD2.5m convertible note (advanced July 2019) is unsecured (subject to negative pledge) with an interest rate of 8% per annum and a maturity date of 19 July 2021. The convertible note is convertible (at MMJ's option) into Sequoya ordinary shares at CAD0.05 each.
- ii. CAD2.5m convertible note facility (executed April 2020) drawn to CAD0.6m, has first ranking security bearing interest of 8% per annum and a maturity date of 15 April 2021. The convertible note is convertible (at MMJ's option) into ordinary shares at CAD0.10 per share.
- iii. 19m ordinary shares (27% shareholding) in Sequoya.

(d) Harvest One (HVT)

MMJ was a foundation investor in HVT – the investment now comprises:

- i. 55,557,994 common shares of HVT (the "Common Shares").
- ii. 17,083,333 Common Share purchase warrants (the "Warrants"). Each Warrant entitles the holder to purchase one Common Share at a price of CAD0.06 at any time until April 3, 2022.

(e) WeedMD

MMJ's investment was made in September 2019 – the investment now comprises:

- i. CAD6m in 8.5% unsecured Convertible Debenture units issued by WeedMD which MMJ has the option to convert into 3.75m shares by 25 September 2022. The debenture units have preference over ordinary shares with interest paid to MMJ on a six-monthly basis.
- ii. Warrants that allow MMJ to acquire an additional 3.75m shares for CAD1.80 each by 25 September 2022.

7. Valuation of Assets

MMJ values its cannabis investments by applying the following principles:

- (a) Listed securities – the book value is based on the closing share prices for public companies at period end converted into Australian dollars at the relevant prevailing foreign exchange rates at month end.
- (b) Unlisted equity securities - The book value is based on the most recent material funding round share prices for private companies converted into Australian dollars at the relevant prevailing foreign exchange rates. In the absence of a recent capital raise or arm's length transaction, management considers all available information, including adjustments which considers an Enterprise Value to Revenue Multiple and/or benchmarking of instruments to market movements indicated by relevant indices. MMJ also takes in to account the recommendations of its asset manager, Embark Ventures, where it is considered that the fair value should be less than recent capital raisings due to outlook for the individual business.
- (c) Convertible debentures and loan instruments – the book value is based on MMJ's assessment of the capacity of the investee to repay principal and interest

The book values also include the unrealised gain arising from valuation of unlisted warrants using the Black-Scholes pricing model. The Black-Scholes attributes a value to warrants which may be "out of the money" at month end. The Black Scholes model is commonly used to determine the fair price or theoretical value for a call, or a put option based on six variables such as volatility, type of option, underlying stock price, time to expiry, strike price, and risk-free rate. The warrant valuation ascribed through Black Scholes assumes that the warrant is exercised on the expiry date of the warrant which may not be the actual outcome e.g. MMJ decides to exercise the warrant prior to expiry.

¹⁰ In November 2020 WeedMe repaid the final instalment of the secured convertible loan advanced by MMJ in July 2019

The Net Asset Value or NAV is calculated after deducting a provision for company tax on any net unrealised gains that may arise on such a theoretical disposal. MMJ does not hedge the carrying value of existing investments denominated in non-AUD currencies.

MMJ's financial statements are subject to statutory audit or review by our independent auditor BDO Audit (WA) Pty Ltd, at 31 December and 30 June each year.

Note:

- a) All information within this release is unaudited unless stated otherwise.
- b) The book value includes shares, convertible notes, options, loans and warrants.

8. Dividend Policy

On 7 June 2019, MMJ announced its intention to distribute 20% of its annual profit after tax after excluding unrealised gains and losses on investments (Annual Profit). The policy first applied in respect of the Annual Profit for the year ended 30 June 2020. The dividend would be payable within three months of each half year after the completion of the half year and annual financial statements. It is MMJ's intention that the dividend would benefit from available franking credits held by MMJ.

9. Investment Policy

MMJ is an Australian-listed company whose core business is holding minority investments across along the cannabis value-chain including cultivation, extraction, crystallisation, product manufacture, retail and patient services. in Australia, Canada and Europe. MMJ is also able to make investments in sectors outside of cannabis, such as but not limited to, natural resources, pharmaceuticals and software services technology.

In November 2020, MMJ's shareholders approved the broadening of the MMJ investment mandate to include strategic investments in sectors outside of cannabis, such as but not limited to, natural resources, pharmaceuticals and software services technology, which will comprise no more than 25% of MMJ's total consolidated assets at the time the investments are made (the Diversification). The Diversification permits MMJ increased flexibility to create growth and greater returns for Shareholders. Through the Diversification, MMJ will target exposure in a range of global opportunities, in addition to the existing investments in the cannabis sector allowing the Company to lower its investment risk and reduce the impact of market volatility from the cannabis sector to ultimately benefit Shareholders.

Glossary

ABBREVIATION	Definition
AUD	means Australian dollars.
AASB	Australian Accounting Standards Board.
ACMPR	means Access to Cannabis for Medical Purposes Regulations.
ASX	means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.
ASX Listing Rules	means the Listing Rules of ASX.
B2B	Business to business
CAD	means Canadian dollars.
CBD	means Cannabidiol (CBD) is a crystalline, nonintoxicating cannabinoid in cannabis and hemp.
CBG	means Cannabigerol is the non-acidic form of cannabigerolic acid, the parent molecule from which other cannabinoids are synthesized.
Company or MMJ	means MMJ Group Holdings Limited (ACN 601 236 417).
EBITDA	means Earnings before Interest, Tax, Depreciation and Amortisation.
GMP	GMP stands for Good Manufacturing Practices and refers to a system of manufacturing that guarantees reproducibility of product quality to set specifications.
LPs	Canada's Licensed Producers of Cannabis Products
M	means million
MMPR	means Marihuana for Medical Purposes Regulation
MOIC	means multiple on invested capital
NTA	means net tangible assets.
Option	means an option to acquire a Share usually at predetermined price.
Share	means a fully paid ordinary share in the capital of the Company.
Shareholder	means a registered holder of a Share.
THC	means THC is the principal psychoactive constituent of cannabis
TSXV	Toronto Stock Exchange Venture
Warrant	means an option to acquire a Share usually at predetermined price.
WST	means Western Standard Time as observed in Perth, Western Australia.